RE:RE:The thesis has changed.StockscoutX wrote: You finally figured it out cactuseskimo.
StageZero will remain a small operating company. It has sufficent revenues to keep the lights open, pay the bills, pay the salaries and some extras for insiders but not enough to grow. CEO and BOD seem to be satisifed with that.
Furthermore, have you ever seen insiders, like StageZero, owning a very low share count of their own stock? They barely own
3.6% of StageZero shares. Goes to show that the goal to increase shareholder value seems to be very far from their minds and decision making process. Therefore, are they really working for shareholders? I will let you figure that one out for yourself.
Moreover, any future expansion will be through massive dilution. Guess what? It will have barely no impact on their side since they don't own much shares. Guess who's going incur more losses? Retailers who bought in the dream.
cactuseskimo wrote: Whoever that basher was (no, it's not me) who over and over and over again stated this was going down to 0.39 must be the second coming of Nostradamus. Holy krap. I thought there was no way in god's green earth we would ever see a price like that, but here we are.
After the big flop release of Aristotle, I got out on the way down at about 85 cents, ending up with a small gain. However, I got back in again at 60 cents thinking I was a genius. Well, I eventually saw the writing on the wall and got out again at 48 cents giving back and profit I had previously made.
It seems tempting to get back in again, but now the bashers are predicting a 20 cent share price, and after what I've just witnessed, who am I to say they are wrong. One thing I do know, is that if you invest in the company, and the price goes down, you ask yourself - has the thesis changed? If it hasn't, then you hold on. With Stagezero though, I eventually had to admit to myself, yeah, the thesis has changed. The original thesis was the mass sale of cancer tests to hospital networks, insurance providers and large corporations. Now, the thesis is a grassroots growth approach starting from a privately owned clinic.
So, yeah, the thesis has definitely changed. They may figure it out eventually, but I think I might take the advice of the bashers for now. They've been right every step of the way so far.
As of December 31, 2020, key management personnel controlled 5.4% (2019-6.2%) of the issued and outstanding common shares of the Company and $612,021 (2019-$649,446) of compensation remains unpaid to current and former key management personnel.
also they have approx 3.3mill shares in options available to exercise into shares
straight from MD&A